학술논문
Peripheral Inhibitor of AChE, Neostigmine, Prevents the Inflammatory Dependent Suppression of GnRH/LH Secretion during the Follicular Phase of the Estrous Cycle.
Document Type
Article
Author
Source
Subject
*INFLAMMATION prevention
*HYPOTHALAMUS anatomy
*ACETYLCHOLINESTERASE
*ANALYSIS of variance
*ANIMAL experimentation
*CHOLINESTERASE inhibitors
*ENZYME-linked immunosorbent assay
*FISHER exact test
*GENE expression
*HUMAN reproduction
*LUTEINIZING hormone
*GONADOTROPIN releasing hormone
*MENSTRUAL cycle
*OVULATION
*PARASYMPATHOMIMETIC agents
*PITUITARY gland
*POLYMERASE chain reaction
*RADIOIMMUNOASSAY
*RESEARCH funding
*SHEEP
*WESTERN immunoblotting
*CONTROL groups
*DATA analysis software
*DONEPEZIL
*DESCRIPTIVE statistics
*UTERINE fundus
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2314-6133
Abstract
The study was designed to test the hypothesis that the inhibition of acetylcholinesterase (AChE) activity at the periphery by Neostigmine (0.5 mg/animal) will be sufficient to prevent inflammatory dependent suppression of the gonadotropin-releasing hormone (GnRH)/luteinising hormone (LH) secretion in ewes in the follicular phase of the estrous cycle, and this effect will be comparable with the systemic AChE inhibitor, Donepezil (2.5 mg/animal). An immune/inflammatory challenge was induced by peripheral administration of lipopolysaccharide (LPS; 400 ng/kg). Peripheral treatment with Donepezil and Neostigmine prevented the LPS-induced decrease (P<0.05) in LHβ gene expression in the anterior pituitary gland (AP) and in LH release. Moreover, Donepezil completely abolished (P<0.05) the suppressory effect of inflammation on GnRH synthesis in the preoptic area, when pretreatment with Neostigmine reduced (P<0.05) the decrease in GnRH content in this hypothalamic structure. Moreover, administration of both AChE inhibitors diminished (P<0.05) the inhibitory effect of LPS treatment on the expression of GnRH receptor in the AP. Our study shows that inflammatory dependent changes in the GnRH/LH secretion may be eliminated or reduced by AChE inhibitors suppressing inflammatory reaction only at the periphery such as Neostigmine, without the need for interfering in the central nervous system. [ABSTRACT FROM AUTHOR]